Catheter ablation of AF  safety and efficacy in DM patients is similar to general population , especially when performed in younger patients with satisfactory glycemic control .
Catheter ablation of AF reduces the amount of patients requiring AADs , an additional benefit in this population commonly exposed to adverse effects of AF pharmacological treatments
AIMS Diabetes mellitus ( DM ) and atrial fibrillation ( AF ) share pathophysiological links , as supported by the high prevalence of AF within DM patients .
Catheter ablation of AF ( AFCA ) is an established therapeutic option for rhythm control in drug resistant symptomatic patients .
Its efficacy and safety among patients with DM is based on small population s , and long-term outcome is unknown .
The present systematic review and meta- analysis aims to assess safety and long-term outcome of AFCA in DM patients , focusing on predictors of recurrence .
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
AIMS The aim of this study was to investigate serious clinical outcomes associated with atrial fibrillation ( AF ) and the effects of routine blood pressure lowering on such outcomes in the presence or absence of AF , among individuals with type 2 diabetes . METHODS AND RESULTS About 11 140 patients with type 2 diabetes ( 7.6 % of whom had AF at baseline ) were r and omized to a fixed combination of perindopril and indapamide or placebo in the Action in Diabetes and Vascular Disease : preterAx and diamicroN-MR Controlled Evaluation ( ADVANCE ) study . We compared total mortality and cardiovascular disease outcomes and effects of r and omized treatment for 4.3 years on such outcomes between patients with and without AF at baseline . After multiple adjustments , AF was associated with a 61 % ( 95 % confidence interval 31 - 96 , P < 0.0001 ) greater risk of all-cause mortality and comparable higher risks of cardiovascular death , stroke , and heart failure ( all P < 0.001 ) . Routine treatment with a fixed combination of perindopril and indapamide produced similar relative , but greater absolute , risk reductions for all-cause and cardiovascular mortalities in patients with AF , compared with those without AF . The number of patients needed to be treated with perindopril-indapamide for 5 years to prevent one cardiovascular death was 42 for patients with AF and 120 for patients without AF at baseline . CONCLUSION Atrial fibrillation is relatively common in type 2 diabetes and is associated with substantially increased risks of death and cardiovascular events in patients with type 2 diabetes . This arrhythmia identifies individuals who are likely to obtain greater absolute benefits from blood pressure-lowering treatment . Atrial fibrillation in diabetic patients should be regarded as a marker of particularly adverse outcome and prompt aggressive management of all risk factors
Catheter ablation of AF  safety and efficacy in DM patients is similar to general population , especially when performed in younger patients with satisfactory glycemic control .
Catheter ablation of AF reduces the amount of patients requiring AADs , an additional benefit in this population commonly exposed to adverse effects of AF pharmacological treatments
AIMS Diabetes mellitus ( DM ) and atrial fibrillation ( AF ) share pathophysiological links , as supported by the high prevalence of AF within DM patients .
Catheter ablation of AF ( AFCA ) is an established therapeutic option for rhythm control in drug resistant symptomatic patients .
Its efficacy and safety among patients with DM is based on small population s , and long-term outcome is unknown .
The present systematic review and meta- analysis aims to assess safety and long-term outcome of AFCA in DM patients , focusing on predictors of recurrence .